Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons

Article English OPEN
Hamelmann, Eckard ; Schauer, Uwe ; Bergmann, Karl-Christian ; Gerstlauer, Michael ; Lehmann, Sylvia ; Gappa, Monika ; Brenneken, Amelie ; Schulz, Christian ; Ahrens, Peter ; Schreiber, Jens ; Wittmann, Michael (2015)
  • Publisher: Co-Action Publishing
  • Journal: European Clinical Respiratory Journal, volume 2 (eissn: 2001-8525)
  • Related identifiers: doi: 10.3402/ecrj.v2.28531, doi: 10.3402/ecrj.v2i0.28531, pmc: PMC4629753
  • Subject: allergen avoidance | airflow therapy | antiasthmatic therapy | anti-asthmatic therapy, allergic rhinitis, exacerbations, airflow therapy, resource use, allergen avoidance, environmental control | exacerbations | Original Research Article | environmental control | resource use | allergic rhinitis

Introduction: Continuous or episodic allergen exposure is a major risk factor of frequent symptoms and exacerbations for patients with allergic asthma. It has been shown that temperature-controlled laminar airflow (TLA) significantly reduced allergen exposure and airway inflammation and improved quality of life of patients with poorly controlled allergic asthma.Objective: The objective was to evaluate the effects of nighttime TLA when used during real-life conditions for 12 consecutive months in addition to the patients’ regular medication.Methods: This multicenter, pre- and postretrospective observational study included patients with inadequately controlled moderate-to-severe allergic asthma who received add-on treatment with TLA for 12 consecutive months. Data on medication use, asthma control, asthma symptoms, lung function, use of hospital resources, and exacerbations were collected after 4 and 12 months and compared with corresponding data collected retrospectively from medical records during the year prior to inclusion in the study.Results: Data from 30 patients (mean age 28; range 8–70) completing 4 months and 27 patients completing 12 months of TLA use are presented. The mean number of exacerbations was reduced from 3.6 to 1.3 (p<0.0001), and the ratio of asthma-related emergency room visits or hospitalizations diminished from 72.4 to 23.3% (p=0.001) or from 44.8 to 20.0% (p<0.05), respectively, after 12 months of TLA use. The Asthma Control Test index increased from 14.1 to 18.5 (p<0.0001). After 4 months of TLA use, clear improvements can be shown for most variables in line with the data collected after 12 months.Conclusions: The addition of TLA to the patients’ regular medication significantly reduced exacerbations, asthma symptoms, and the utilization of hospital resources. The data support that TLA may be an important new non-pharmacological approach in the management of poorly controlled allergic asthma.Keywords: antiasthmatic therapy; allergic rhinitis; exacerbations; airflow therapy; resource use; allergen avoidance; environmental control(Published: 29 July 2015)Citation: European Clinical Respiratory Journal 2015, 2: 28531 - http://dx.doi.org/10.3402/ecrj.v2.28531
  • References (33)
    33 references, page 1 of 4

    1. Tunnicliffe WS, Fletcher TJ, Hammond K, Roberts K, Custovic A, Simpson A, et al. Sensitivity and exposure to indoor allergens in adults with differing asthma severity. Eur Respir J. 1999; 13: 654 9.

    2. Peroni DG, Piacentini GL, Costella S, Pietrobelli A, Bodini A, Loiacono A, et al. Mite avoidance can reduce air trapping and airway inflammation in allergic asthmatic children. Clin Exp Allergy. 2002; 32: 850 5.

    3. Piacentini GL, Bodini A, Costella S, Vicentini L, Peroni D, Zanolla L, et al. Allergen avoidance is associated with a fall in exhaled nitric oxide in asthmatic children. J Allergy Clin Immunol. 1999; 104: 1323 4.

    4. Rijssenbeek-Nouwens LH, Fieten KB, Bron AO, Hashimoto S, Bel EH, Weersink EJ. High-altitude treatment in atopic and nonatopic patients with severe asthma. Eur Respir J. 2012; 40: 1374 80.

    5. Grootendorst DC, Dahlen SE, Van Den Bos JW, Duiverman EJ, Veselic-Charvat M, Vrijlandt EJ, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin Exp Allergy. 2001; 31: 400 8.

    6. Peroni DG, Boner AL, Vallone G, Antolini I, Warner JO. Effective allergen avoidance at high altitude reduces allergeninduced bronchial hyperresponsiveness. Am J Respir Crit Care Med. 1994; 149: 1442 6.

    7. Custovic A, Simpson A, Chapman MD, Woodcock A. Allergen avoidance in the treatment of asthma and atopic disorders. Thorax. 1998; 53: 63 72.

    8. Platts-Mills TA, Vaughan JW, Carter MC, Woodfolk JA. The role of intervention in established allergy: avoidance of indoor allergens in the treatment of chronic allergic disease. J Allergy Clin Immunol. 2000; 106: 787 804.

    9. Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J. 2001; 17: 589 95.

    10. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004; 170: 836 44.

  • Metrics
    No metrics available
Share - Bookmark